A study found that in endometrial cancer, TRIM14 can activate the classical IκB Kinase (IKK) complex by binding to NF-κB Essential Modulator (NEMO), leading to the phosphorylation of IκBα, releasing NF-κB from its inhibitory state, thereby driving the activation of its signaling pathway and accelerating tumor progression [29]. Here, NFKB1 is linked to endometrial cancer.